Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

NCT06685718 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06685718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06685718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Terminated
Start date
December 5, 2024
Completion date
April 21, 2026
Enrollment
33 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, egfr mutation-related tumors, lung cancer, non-small cell lung cancer, nsclc, nsclc (non-small cell lung carcinoma)